Core One Labs has announced that its subsidiary Vocan Biotechnologies has successfully tested its proof-of-concept for the production of biosynthetic N-methyltryptamine (NMT) (also known as monomethyl tryptamine (MMT)) for use in future upscaling capabilities. NMT, which belongs to the family of tryptamines, is an organic alkaloid compound known to produce psychoactive effects when combined with a monoamine oxidase A inhibitor (MAOI).
Category Press Release
Published in GlobeNewswire
Companies Featured
Core One LabsWe will deliver cGMP API grade psilocybin for use by drug organizations, API makers and associations leading clinical preliminaries
Vocan Biotechnologies
Vocan is a genetic engineering and biosynthesis firm currently focused on producing pharmaceutical grade psilocybin